UPLOAD Filing
Spyre Therapeutics, Inc.
Date: June 2, 2025 · CIK: 0001636282 · Accession: 0000000000-25-005782
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-37722
Letter
Re: Spyre Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 27, 2025 File No. 001-37722 Dear Scott Burrows:
June 2, 2025
Scott Burrows Chief Financial Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23 Suite 105 Waltham, MA 02453
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 2, 2025 Scott Burrows Chief Financial Officer Spyre Therapeutics, Inc. 221 Crescent Street Building 23 Suite 105 Waltham, MA 02453 Re: Spyre Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed February 27, 2025 File No. 001-37722 Dear Scott Burrows: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>